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SUMMARY 
Myelodysplastic syndromes (MDS) share many features with acute myeloid leukemias 
(AML) and in fact 20 - 40% of the patients eventually develop a picture of full blown 
AML. Chromosome 7 has been a focus of attention as a site harboring tumor suppressor 
genes whose loss of function contributes to leukemia transformation or tumor 
progression. Abnormalities of chromosome 7 are frequently encountered in AML and 
MDS. The aim of the present study was to detect the molecular abnormalities of 
chromosome 7 in Egyptian AML and MDS patients using the FISH technique and 
whether the abnormality has an implication on the prognosis of the disease after a 
period of one year follow up. Fluorescence in-situ hybridization (FISH) was performed 
for chromosome 7 using a locus specific probe for 7q31 and a centromeric probe from 
7p11.1-q11.1 in a series of 30 patients diagnosed as: AML (20 patients) and MDS (10 
patients) according to the FAB criteria. Aberrations of Chromosome 7 were found in 
36.6% of AML patients: 3 cases showing monosomy with a mean positivity of 17.3%, 2 
cases showing 7q deletion with a mean positivity of 11%. While both monosomy and 
deletion were detected in 3 cases.  However, in MDS patients; monosomy for 
chromosome 7 was the only abnormality detected and was found in 30% of cases. 
Genetic abnormality of chromosome 7 showed a significant association with poor 
prognostic criteria. Patients who had normal FISH results showed a higher percentage 
(31.6%) of complete remission (CR) versus 0% in patients with monosomy or deletion 
who showed a higher percentage (100%) of death or poor response to therapy (NR). 
Although AML patients had a worse prognosis when compared to MDS patients, 
patients with genetic abnormalities showed the worst outcome. 
[Afr J Health Sci. 2006;13:33-42] 
Introduction 
The long arm of human chromosome 7 between 
7q22 and 7q36 has been identified as a region 
harboring one or more tumor-suppressor genes 
(TSGs) inactivated in acute myeloid leukemia 
(AML) [1]. Allelotyping studies have delineated at 
least three distinct loci that are frequently deleted 
[2, 3]: 7q22, 7q31.1, and 7q31.3. Among these, a 
correlation between survival and deletion limits 
implicates loss in the cytogenetic bands 7q31~q32 
in refractoriness to therapy [4, 5]. 
Complete and interstitial losses of 
chromosome 7 (-7, 7q-) are nonrandom anomalies 
seen in de novo and therapy-induced myeloid 
neoplasms as well as leukemias arising from 
occupational or environmental exposure to 
mutagens. Monosomy 7 in adult myeloid 
neoplasms, is more common than the interstitial 
deletions of the long arm (7q-). The importance of 
monosomy 7 is evident from the small but 
significant number of adult acute myeloid leukemia 
(AML) cases in which it occurs as the sole anomaly 
[6]. Childhood monosomy 7 seen secondary to  
 
Fanconi’s anemia, juvenile chronic myeloid 
leukemia, Down’s syndrome as well as familial 
monosomy 7 may share genetic alterations 
associated with   adult myeloid neoplasms [7].  The  
poor prognosis associated with chromosome 7 
anomalies in adult myelodysplasia (MDS) and 
AML underscores the need for molecular analysis 
[8, 9]. 
Interstitial deletions of 7q, seen in a variety of 
solid tumors with distinct segments of loss at bands 
7q11, 7q22, and 7q31 that are apparently unique to 
specific neoplasms, have raised the possibility of a 
number of tumor suppressor genes in the long arm 
of chromosome 7 [10]. In the past, delineation of 
the critical regions of loss in 7q has been the focus 
of several investigations on solid tumors as well as 
hematopoietic neoplasms [11-13]. Fluorescence in 
situ hybridization analyses have delineated a 
critical region of loss at 7q22 in myeloid 
malignancies [14]. Other studies have raised the 
possibility of unbalanced translocations of 
fragments of chromosome 7 being located on 
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marker chromosomes; patients who were perceived 
to be monosomic by centromere-specific probes 
showed strong hybridizations to marker 
chromosomes with chromosome 7-painting probes 
[15]. However, the extent and variability of 7 q 
deletions have so far prevented the identification of 
a putative tumor suppressor gene. The molecular 
mechanisms underlying these chromosomal 
abnormalities also remain unclear. Other 
investigators have identified a number of sequence 
elements/motifs that are frequently present near the 
breakpoints of chromosomal rearrangements and 
may suggest how these rearrangements occurred. 
They include Alu repeats, chi-like sequences, DNA 
topoisomerase II consensus binding sites and 
sequences with homology to the heptamer and 
nanomer motifs of the V(D)J recognition signal  
sequence [16]. Accordingly, the present study 
aimed to detect monosomy 7and 7q31 deletions 
among AML and MDS patients using FISH probes 
and to correlate whether the abnormality has an 
implication on the prognosis or response to 
therapy. 
 
Materials and Methods 
Patients 
Forty samples were included in this study. Twenty 
AML and Ten MDS patients who were newly 
diagnosed in Al Kasr El-Aini Hospital over a 
period of 2 years from January 2002 to January 
2004 were enrolled in this study. Their ages ranged 
from 20-65 years with a mean of 41 years and the 
male to female ratio was 1.1.  The diagnosis and 
sub classification of MDS and AML was based on 
morphological and cytochemical studies of 
peripheral blood (PB) smears, bone marrow (BM) 
aspirates, and biopsy specimens obtained before 
therapy, and immunophenotyping (Table 
1)according to the French-American-British 
Cooperative Group criteria [17,18]. Ten age 
matched controls were involved to normalize FISH 
results. Complete hemogram and biochemical tests 
were done to the control group before the FISH 
analysis which was done on PB samples. 
 
Immunophenotyping 
10ul EDTA blood from each case was mixed with a 
panel of monoclonals; CD45,34,13,14,33&38 (all 
purchased from Becton-Dickinson) after RBC’s 
lysis and  processed according to the 
manufacturer’s guide. Analysis was performed on 
FACScan (Becton-Dickinson), lymphocytes or 
blasts were gated on a forward and side scatter 
profiles (>20% positivity were considered positive) 
[19].
 
                               Table 1: FAB subtypes of the studied groups  
FAB subtype No. of cases (30) Frequency 
M1 4/20 20% 
M2 3/20 15% 
M3 3/20 15% 
M4 6/20 30% 
M5 4/20 20% 
RA 7/10 70% 
RAEB 3/10 30% 
 
Culture 
Fresh peripheral blood PB samples were obtained 
from the control group and fresh bone marrow 
samples were used for all 30 MDS and AML cases. 
Mononuclear cell layer was separated using ficol 
hypaque density gradient centrifugation from both 
PB and BM samples [20]. 
        Mononuclear cells were cultured for 24 h 
(short-term cell culture) without PHA. Five 
milliliters of RPMI 1640 medium supplemented 
with 15% of fetal calf serum and 1% L-glutamine 
were added to each culture tube. The cell 





1x106/ml. Colcemid at a final concentration of 0.05 
µg/ml was added 60 min before harvesting. Cells 
were treated with 0.075 MKCl hypotonic solution 
at 37°C for 15 min followed by three changes of 
3:1 methanol:glacial acetic acid fixative solution. 
The cells were finally resuspended in this fixative 
solution. The cells suspended in fixative solution 
were spread on slides in a Thermotron (CDS-5) at 
30°C and 40% of humidity. The slides were put in 
a 2x SSC ( 1x SSC =150 mM sodium chloride and 
15 mM sodium citrate solution) bath at 37°C for 30 
min and then dehydrated in 70%, 80% and 100% 
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ethanol. After air-drying the slides, FISH 
procedures were performed [21]. 
 
FISH 
FISH analysis was performed using the 
commercially available locus specific identifier, 
LSI D7S522 Spectrum Orange/ CEP 7 Spectrum 
Green Dual Colour probe which hybridizes to band 
7q31 (Spectrum Orange LSI D7S522) and to the 
centromere band region 7p11.1-q11.1, locus D7Z1 
(Spectrum Green CEP 7) of human chromosome 7 
(Vysis, Downers Grove, IL USA) according to the 
manufacturer’s instructions. Improvements were 
obtained by incubating bone marrow slides at room 
temperature overnight before digestion with 
proteinase K (stock solution 1mg/ml) for 6 min at 
37°C. After washing twice with phosphate buffer 
solution lx, slides were fixed in a 1% formaldehyde 
solution; they were then denatured in 70% 
deionized formamide/2xSSC solution for 5 min at 
74°C then successively passed through70%,80% 
and 100% ethanol at -20°C. The probe was 
denatured at 74°C for 5 min and added onto the 
slide and then covered with a coverslip. 
Hybridization was performed overnight at 37°C in 
a humidified chamber. Post-hybridization washing 
was done in 4xSSC NP 40 for 2 min at 74°C first 
and then for 2 min at room temperature. Slides 
were counterstained and mounted with DAPI II.            
  














Image analysis and scoring 
Images were viewed under the fluorescent 
microscope with the proper filter set: DAPI 
/orange/green were used to visualize the 
fluorescent signals. A total of 500 interphase and 
metaphase nuclei were analyzed using Vysis 
scoring criteria blindly scored by two individuals 
for each sample. The pictures were captured by 
using an Olympus BX60 microscope equipped with 
compulog IMAC-CCD S30 camera module and the 
insitu imaging system (ISIS 2) software version 2.5 
(MetaSystem, Belmont, MA,USA). using x 100  
objective lens. The centromere appeared as a green 
signal while 7q31 appeared as an orange signal. 
The number of fluorescent signals for each nucleus 
was noted as:  
4 signals: 2 green and 2 orange were counted as a 
normal cell. 
3 signals: 1 orange and 2 green indicated deletion 
(7q-). 
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2 signals: 1 green and 1 orange indicated 
monosomy 7 (-7). 
0 (no signal could be seen): failure of 
hybridization, excluded Split signal: 2 signals with 
very short distance in-between were counted as 1 
signal. Occasionally the probe may appear as five 
to six signals depending on the condensation of the 
DNA and relative distance between chromatids. 
The signals may appear diffuse or split. In normal 
metaphase, LSI D7S522 may appear as 1 to 2 
signals on each chromosome 7. Normal control 
specimens were incorporated and the cut off level 




Fig 2: FISH for chromosome 7 showing four signals of 3 interphase nuclei (normal): 2 green signals 



































Fig 3: FISH for chromosome 7 showing four signals of a metaphase nucleus (normal): 2 green signals 
(internal control) representing the centromere of chromosome 7 and 2 red signals representing 7q31 in 
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The 40 cases were classified into 3 groups: Group 
A; 20 AML patients, Group B; 10 MDS patients 




Chromosome 7 abnormalities were detected in 
36.6% (11/30) of the patients. Eight patients were  
AML and 3 patients were diagnosed as MDS, 
Table 2 summarizes the type of abnormality 




                             
                           Table 2: Frequency of chromosome 7 abnormalities in the study group 
Monosomy7(-7) 7q deletion(-7q31) Both Cases 
Frequency Frequency Frequency 
AML (20) 3/20   15% 2/20   10% 3/20  15% 
MDS (10) 3/10   30% 0/10    0% 0/10    0% 
 
 
Fig 4: FISH for chromosome 7 showing three signals: 2 green (internal control) and 1 red signal 
representing deletion of  7q31(-7q) 















Fig 5: FISH for chromosome 7 showing two signals: 1 green and 1 red signal representing monosomy for 
            chromosome 7 (-7)        
 
  
                                                             
 
Association between the clinical, 
hematological data and the cytogenetic study 
A higher predominance of females; 9 females 
versus 2 males, was found in patients with 
chromosome 7 anomaly and the difference         
was statistically significant (P=0.02). The 
anomalies were also associated with splenomegaly 
and lymphadenopathy (P-value 0.034 and 0.043 
respectively). Moreover, patients with 
Chromosome 7 abnormality showed a significantly 
higher mean TLC and PB blast cell counts (P=0.03 
and 0.01 respectively). Of the 8 AML cases 
showing chromosome 7 abnormality, 3/6 (50%) 
cases were M4 phenotype, 3/4 (75%) cases were 
M5 phenotype while 1/4 (25%) case was M1 and 
1/3 (33%) case was M2. While the 3 monosomic 
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MDS cases were Refractory anemia with excess 
blasts (RAEB) (none was refractory anemia [RA]). 
However there was no significant association 
between the type of leukemia and the chromosomal 
abnormality (data not shown). 
 
Association between the clinical oqutcome 
and the cytogenetic study 
Patients were followed up for a period of one year, 
6 patients entered in complete remission (CR), 
(BM. samples were morphologically and 
immunophenotypically normal). MDS patients who 
turned to AML and AML patients who relapsed or 
failed to enter in complete remission were 
considered non responders to therapy (NR), these 
were 17 patients [21]. Patients who died due to 
relapse, organ failure or therapy related mortality 
were considered “Died”, and they were 7 patients. 
Patients who had normal FISH results showed a 
higher percentage of complete remission CR while 
patients with monosomy or deletion had higher 
rates of death or showed no response to therapy 
(NR) (p =  0.03) (Fig6) 
 
          




















            CR: complete remission 
            NR: No response to therapy 
 
FISH results were also interpreted quantitatively; 
the number of positive nuclei was counted. These 
results also revealed a worse prognosis towards 
those who had a higher percentage of the genetic 
abnormality and the p-value was 0.027 (Table 3). 
 
             Table 3: Association between outcome and quantitative FISH results  
Prognosis  N Quantit. FISH mean% ±S.D.   p-value  Significance 
CR  6 (20%)  0.83 ± 1.60 
Died or NR  24 (80%)  3.12 ± 3.36 
 0.027  Significant 
 
 
              Table 4: Comparison between outcome of AML and MDS cases 
 Diagnosis  p-value  Significance  Outcome 
 MDS  AML 
 CR(6)  2 (33%)  4 (67%) 
 NR(17)  8(47)  9 (53%) 
 Died(7) -  7 (100%) 
   0.03  Significant 
  
Comparison between AML and MDS: 
On comparing AML with MDS cases regarding the 
outcome, AML patients had a worse outcome   (P = 
0.03) (Table 4). Comparison between MDS and 
AML patients with the anomalies was not done due 
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The association between losses in the 7q region and 
the appearance of myeloid leukemia suggests that 
this region contains tumor suppressor gene(s) 
whose loss of function contributes to leukemia 
transformation or tumor progression but definitive 
evidence for their role has not been yet established. 
[11,24]. The complexity of 7q rearrangements 
suggests that a synergy of different genetic factors, 
rather than the alteration of a single tumor 
suppressor gene, could be involved in the 
pathogenesis of del (7q) in myeloid disorders [25]. 
On the basis of cytogenetic and molecular methods, 
several critical regions in 7q have been identified in 
chromosome bands: 7q22, 7q31.1, 7q32, 7q33-34 
and 7q35-36 [26]. 
Aberrations of chromosome 7 are usually 
difficult to determine because of the heterogeneity 
of breakpoints and their occurrence in complex 
karyotypes, which are difficult to analyze 
cytogenetically. Complex karyotypes with multiple 
unbalanced translocations are observed in most 
cases of AML with –7/7q- . Thus, in many cases, 
fluorescent in situ hybridization (FISH) analysis 
may be helpful in revealing the involvement of this 
chromosome in structural aberrations. Taking into 
consideration the sensitivity of this technique, it 
can also confirm the numerical aberrations of 
chromosome 7, even when they occur in small 
populations of cells. Since –7/7q- aberrations are 
considered as a poor prognostic factor in malignant 
myeloid disorders, establishing their presence is 
very important from the clinical point of view [27]. 
Thus, the aim of the present work was to detect the 
molecular abnormalities of chromosome 7 
(monosomy 7 and 7q del, –7/7q-) in MDS and 
AML patients using the FISH technique and 
whether it has an implication on the prognosis of 
these diseases.  
Abnormalities of Chromosome 7 were found 
in 40% of patients in Group A and 33% of patients 
of Group B. However, the AML group (Group A) 
revealed both abnormalities, –7/7q- while 
monosomy 7 (–7) was the only abnormality found 
in Group B. Similar frequencies were observed by 
Brozek et al [9] and Chang et al. [28], the latter 
studied chromosomal abnormalities in 52 primary 
MDS patients in which abnormalities involving 
chromosome 7 was the most frequent cytogenetic 
abnormality and was found in 31% of cases. These 
were higher than previously observed by other 
authors, who detected -7/7q- in 12%,8% , 9% ,  
7.8% of AML patients respectively [29,30,31,32]. 
Others revealed monosomy 7 in 8% and 7q- in 5% 
of AML cases [33]. 
Most of our cells failed to enter in metaphase and 
the count was carried on interphase cells yielding 
this relatively high frequency of Chromosome 7 
aberrations which according to Brizard et al [34] 
would have given a lower percentage if metaphase 
cells were studied. This may also yield 
discrepancies between results of interphase FISH 
and conventional cytogenetics (CC) carried on 
metaphase spreads as detected by Kadam et al [35]. 
They explained that the aberrant clone are in G0 at 
the time of examination by CC or the inability to 
enter mitosis in vitro thereby passing undetected by 
metaphase examination [36]. They concluded that 
certain chromosomal aberrations e.g. those 
involving chromosome 7 are underestimated by G-
banding as a result of 2 factors: a) some cells do 
not proliferate in culture and hence cannot be 
karyotyped and b) others give rise to poor 
morphology metaphases which are excluded from 
the scoring.  
Direct evidence for three distinct segments of 
chromosomal loss in the bands 7q22–31 have been 
identified [26]. Liang et al [37] found that more 
than 80% of their AML cases revealed allele loss 
for the entire region, a rare case of the 7q- 
chromosome showed allele loss for only the 
proximal 7q31.1 loci flanked by the markers 
D7S486 and D7S2456. Also, one of their cases 
with monosomy 7 revealed allele loss for loci at 
both 7q31 and 7q22 with retention of sequences 
between these sets of loci. Furthermore, a case of 
AML with no cytogenetic anomaly of chromosome 
7 revealed a submicroscopic allelic imbalance for a 
third distal locus, D7S677. These findings suggest 
the presence of three distinct critical loci that may 
contribute alone or in combination to the evolution 
of MDS and AML. The data also provide 
molecular evidence for unbalanced translocation 
with noncontiguous deletions, as an alternate 
mechanism underlying monosomy 7. This may also 
suggest that some of our patients may have had 
abnormalities in chromosome 7 outside 7q31 with 
intact chromosome 7 centromere, thus giving false 
normal results which reflects an underestimation of 
the frequency of the anomaly 
Monosomy of chromosome 7 was detected in 
6 of our patients (3MDS and 3AML) with a mean 
FISH positivity of 17.3% and 7q deletion was 
detected in 2 cases (AML) with a mean positivity 
of 11% while both monosomy and deletion were 
detected in 3 cases of the whole studied group as 
shown in Table 2. These 3 cases were 2 males and 1 
female, 2 of which had splenomegaly, 
hepatomegaly and lymphadenopathy. All of them 
had monocytic leukemias and none showed CR (2 
of them died and 1 showed NR). There was a 
significant association between the presence of 
splenomegaly, lymphadenopathy, high TLC and 
peripheral blood (PB) Blast cell count with the 
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presence of genetic anomaly, indicating the poor 
prognostic nature of chromosome 7 anomalies [38] 
Aneuploidy of chromosome 7 was more 
frequently or the sole abnormality encountered in 
our MDS cases especially in the refractory anemia 
with excess blasts (RAEB) FAB subtype. 
Chromosome 7 aberrations were not encountered in 
M3 FAB subtype cases, in contrast to M4 and M5 
cases in which they were frequently encountered. 
This may be attributed to the less favorable 
prognosis of M5 with extramedullary infiltration; 
gum infiltration and CNS disease [39]. 
Patients who had normal FISH results (19 
patients) showed a higher percentage (31.6%) of 
complete remission (CR) versus 0% in patients 
with monosomy or deletion (11 patients) who never 
entered in CR (100%) and either died or showed no 
response to therapy (NR). Similar data were 
reported by other authors [9,11]. In the study by 
Brozek et al only 21% of patients with these 
abnormalities reached complete remission, showing 
a bad prognosis and poor response to therapy in the 
group of -7/7q- patients [9]. Quantitative FISH 
results also revealed a worse prognosis towards 
those who had a higher percentage of genetic 
abnormality.  
AML patients had a worse outcome when 
compared to MDS patients. This is obvious from 
the pathogenesis of both diseases where in AML 
the normal marrow elements are replaced 
sometimes totally by the malignant blasts, whereas 
in MDS, there is insufficient differentiation 
capacity of the progenitors to mature blood cells 
[40]. Clinically, malignant myeloid disorders 
exhibiting -7/7q- have been associated with bad 
prognosis with high susceptibility to infections, 
poor response to chemotherapy, and short survival 
times [11,41]. 
Studies demonstrated that FISH provides a 
rapid, quantitative method for the detection of cells 
with chromosome abnormalities in peripheral blood 
and bone marrow specimens. FISH could detect 
MRD in specimens that seemed normal by all 
standard morphological and cytogenetic criteria. 
Since FISH can be applied to interphase cells, 
results can be representative of the entire 
populations rather than restricted to cycling cells as 
is the case with routine cytogenetic analysis. 
Furthermore, the hybridization time will allow 
pretreatment investigations and disease monitoring 
to be performed directly on bone marrow smears 
with results available on the day of specimen 
collection. Also, the small amount of material 
required for FISH examination is particularly 
useful in hypocellular marrows and when 
aspiration is difficult [42]. Chromosome 7 
abnormalities are heterogenous and some are part 
of unexpected complex rearrangements often 
impossible to detect or interpret correctly without 
using FISH techniques. Also, deletions may be 
accompanied by translocations which are 
identifiable only by FISH [43]. 
Diagnostic accuracy in acute leukemias can be 
improved if traditional morphology and 
cytochemsitry are supplemented with 
immunophenotyping and genotypic analysis. This 
multiparameter approach is of crucial importance 
for the management of patients as it enables the 
identification of leukemic syndromes with distinct 
biological features and response to treatment. 
Cytogenetic findings can be quite helpful in 
establishing the correct diagnosis and can add 
information of prognostic significance [44]. They 
help in the diagnosis, prognosis, monitoring and 
therapy decisions [32]. 
 
Conclusion 
While FISH will not replace routine karyotypic 
analysis of material at presentation, it does provide 
a powerful and sensitive tool for monitoring the 
disease in patients with karyotypic abnormalities. 
Thus the detection of chromosome 7 abnormalities 
by FISH is very important since this chromosome 
harbors tumor suppressor genes so this allows 
better understanding of the mechanism of 
leukemogenesis and the molecular categorization 
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